Product category:
Clinical chemistry analysis
News Release from: Myconostica | Subject: FXG:Resp (Asp+)
Edited by the Laboratorytalk Editorial
Team on 31 October 2007
Fast diagnostics for respiratory fungal
infections
FXG:Resp (Asp+) is a multiplex, real-time PCR-based product used for the diagnosis of Aspergillus and Pneumocystis fungi, the common causative agents of life-threatening respiratory infections
FXG: Resp (Asp+) is a diagnostic product that provides clinicians with reliable and accurate results for two of the most common fungal diseases in less than half a day, enabling them to make faster decisions and to potentially start treatment earlier than was possible before The showcase follows successful clinical evaluation of FXG:Resp (Asp+) and the CE marking of Myconostica's efficient fungal DNA extraction kit (MycXtra) to European member countries
This article was originally published on Laboratorytalk on 6 Nov 2002 at 8.00am (UK)
Related stories
Haematology analyser fills gap in range
With a throughput of 80 samples per hour, this will suit laboratories with workloads of up to 350 samples per day and fills the gap between 60 and 120 sample per hour machines
Innovative new products emphasise R and D
Completely new bench-top analyser combines the latest technological advances and a large test menu with a faster throughput
Myconostica plans further performance evaluation studies to support the products.
Both are being showcased at the prestigious Trends in Medical Mycology Conference (Timm), Torino, Italy.
Over ten million people are at risk of life threatening respiratory fungal infections in Europe and North America each year.
Further reading
Getting the right haematology mix, automatically
Latest development to haematology analyser range incorporates a cutting edge fully integrated data management system that enables onboard validation of results
Neurite outgrowth assays for primary screening
High throughput, live cell, neurite outgrowth screens can be performed in 384 well plates at rates exceeding 30,000 compounds per day without compromising data quality
However, current methods for fungal diagnostics are inherently slow and imprecise, relying mainly on culturing patient samples (which takes overs three days).
This may lead to a poor diagnosis and contribute to a high mortality.
In contrast, in less than half a day Myconostica's FXG:Resp (Asp+) diagnostic product accurately, specifically and reliably identifies whether the fungi Aspergillus and/or Pneumocystis are causing the infection.
Commenting on the CE marking and showcasing of Myconostica's first products, David Denning, chief executive and research director of Myconostica said: "Attaining CE mark approval for MycXtra is an important step for Myconostica and the FXG product range will answer the need for rapid diagnostics for disease-causing fungi in respiratory and other clinically relevant tissues and body fluids".
Richard Morgan, chief executive officer of Amphion Innovations, a leading investor in Myconostica, said: "CE marking of MycXtra, and FXG:Resp (Asp+) nearing the market, represents a major milestone for the company".
"These products will have a extreme impact not only on the field of fungal diagnostics but also on the patients who currently have a lengthy wait for their test results".
Myconostica says its FXG family of diagnostic tests accurately, specifically and reliably identifies fungal causes of infection in less than half a day to enable doctors and clinicians to diagnose and treat life-threatening fungal infections, thereby reducing patient mortality rate, hospital residence time and healthcare costs.
The company was founded by David Denning, professor of medicine and medical mycology, University Hospital South Manchester.
Today, it employs a team of research, product development and marketing professionals and managers who are developing and supplying a rich pipeline of innovative products and services for the diagnosis of life-threatening fungal diseases that will be launched over the next years.
• Myconostica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
